Medicus Pharma (MDCX) Competitors $2.22 -0.23 (-9.39%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MDCX vs. CRBP, SKYE, ADAG, COYA, SPRO, BMEA, HLVX, SAVA, ANEB, and ONCYShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Corbus Pharmaceuticals (CRBP), Skye Bioscience (SKYE), Adagene (ADAG), Coya Therapeutics (COYA), Spero Therapeutics (SPRO), Biomea Fusion (BMEA), HilleVax (HLVX), Cassava Sciences (SAVA), Anebulo Pharmaceuticals (ANEB), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. Medicus Pharma vs. Its Competitors Corbus Pharmaceuticals Skye Bioscience Adagene Coya Therapeutics Spero Therapeutics Biomea Fusion HilleVax Cassava Sciences Anebulo Pharmaceuticals Oncolytics Biotech Medicus Pharma (NASDAQ:MDCX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment. Do analysts rate MDCX or CRBP? Medicus Pharma currently has a consensus price target of $23.50, suggesting a potential upside of 958.56%. Corbus Pharmaceuticals has a consensus price target of $49.00, suggesting a potential upside of 400.51%. Given Medicus Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Medicus Pharma is more favorable than Corbus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Which has stronger valuation and earnings, MDCX or CRBP? Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicus PharmaN/AN/A-$11.16M-$1.34-1.66Corbus PharmaceuticalsN/AN/A-$40.21M-$4.76-2.06 Do insiders & institutionals have more ownership in MDCX or CRBP? 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 11.2% of Medicus Pharma shares are owned by company insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is MDCX or CRBP more profitable? Corbus Pharmaceuticals' return on equity of -43.65% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Medicus PharmaN/A -549.30% -228.06% Corbus Pharmaceuticals N/A -43.65%-39.62% Does the media favor MDCX or CRBP? In the previous week, Medicus Pharma had 9 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 10 mentions for Medicus Pharma and 1 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.11 beat Medicus Pharma's score of -0.10 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMedicus Pharma beats Corbus Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.55M$3.12B$5.83B$9.78BDividend YieldN/A2.23%4.40%4.06%P/E Ratio-1.6621.0031.3026.05Price / SalesN/A356.92455.29117.98Price / CashN/A44.5038.0259.36Price / Book12.338.129.536.60Net Income-$11.16M-$54.72M$3.26B$265.65M7 Day Performance13.27%2.62%2.13%1.99%1 Month Performance-26.49%3.25%3.21%0.45%1 Year PerformanceN/A10.82%30.18%18.88% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus Pharma1.8715 of 5 stars$2.22-9.4%$23.50+958.6%N/A$39.55MN/A-1.66N/ANews CoverageAnalyst ForecastGap DownCRBPCorbus Pharmaceuticals4.324 of 5 stars$9.20-0.3%$49.00+432.9%-83.6%$112.77MN/A-1.9340Positive NewsSKYESkye Bioscience1.6865 of 5 stars$3.55+1.3%$15.50+337.2%-44.7%$109.86MN/A-3.3411News CoverageInsider TradeADAGAdagene3.0422 of 5 stars$2.27+9.4%$7.00+209.1%-19.0%$106.70M$100K0.00260News CoverageGap DownCOYACoya Therapeutics1.8633 of 5 stars$6.29+2.2%$16.50+162.5%+11.7%$105.12M$423.45K-5.076SPROSpero Therapeutics3.9598 of 5 stars$1.87+1.9%$5.00+168.1%+36.5%$104.96M$47.98M-1.90150BMEABiomea Fusion3.2174 of 5 stars$1.77-0.8%$16.80+851.8%-76.0%$104.44MN/A-0.5850HLVXHilleVax1.1562 of 5 stars$2.07-0.2%$2.00-3.1%+6.2%$103.54MN/A-1.4420SAVACassava Sciences1.9547 of 5 stars$2.14-0.2%$2.00-6.3%-92.9%$103.14MN/A-0.8430Positive NewsANEBAnebulo Pharmaceuticals2.1718 of 5 stars$2.50-0.8%$5.50+120.0%+24.4%$102.70MN/A-9.624Positive NewsONCYOncolytics Biotech1.6917 of 5 stars$1.00-1.0%$5.00+400.0%+2.0%$100.36MN/A-3.7030Gap Down Related Companies and Tools Related Companies Corbus Pharmaceuticals Alternatives Skye Bioscience Alternatives Adagene Alternatives Coya Therapeutics Alternatives Spero Therapeutics Alternatives Biomea Fusion Alternatives HilleVax Alternatives Cassava Sciences Alternatives Anebulo Pharmaceuticals Alternatives Oncolytics Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDCX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access